Cambridge, MA · Founded 2017 · Privately Held (backing)
Developer of brain-penetrant and peripherally-restricted small molecules designed to slow or modify the progression of neurodegenerative and cardiorenal diseases. Eikonizo Therapeutics is based in Cambridge, MA and was founded in 2017. It was valued at $54 million at its later-stage round in Dec 2023, the last priced event on record. It has raised $46.1 million across 2 recorded rounds; the latest was a $371,352 seed round in May 2018.
PMV mark · valuation
$54.0M
Oct 2026
Priced at
its later-stage round
Dec 2023
Total raised
$46.1M
Last round
Seed Round
May 2018
No prints on record
No secondary trades in Eikonizo Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Eikonizo Therapeutics with a free account
·Watch Eikonizo Therapeutics: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Eikonizo Therapeutics stock.
